# Peptides for Depression & Mood: Evidence Review (2026)

> A clinical, evidence-graded look at the three peptides marketed for depression — Cerebrolysin, Selank and Semax — separating secondary-endpoint human data and preclinical antidepressant signals from marketing hype.

*Published 2026-07-01 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
The human evidence that any peptide *treats depression* is weak, indirect and mostly secondary. **There is no dedicated, adequately powered Western RCT of any of these peptides for major depressive disorder.** The best case — **Cerebrolysin (Grade B)** — rests on depression measured as a *secondary* endpoint in stroke and TBI trials, and even that is mixed.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) Selank and Semax carry only preclinical antidepressant signals.[9](https://peptidevox.com/#r9)[16](https://peptidevox.com/#r16) None is FDA-approved; all should be treated as prohibited in sport.[22](https://peptidevox.com/#r22)

This is an honest, evidence-graded ranking of the peptides circulating for depression and low mood — Cerebrolysin, Selank and Semax. Ranking reflects the strength of *human* evidence specifically for depression, not fame, mechanism elegance, or evidence for other conditions. By that standard the field is thin.

*This article is informational and editorial content only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Depression is a serious, treatable and potentially life-threatening medical condition; these peptides are unapproved investigational compounds. No peptide here is an FDA-approved antidepressant or a substitute for evidence-based care — psychotherapy, FDA-approved medication where indicated, and, for severe cases, treatments such as ketamine/esketamine, TMS or ECT delivered by a licensed clinician. If you are in crisis or thinking about suicide, in the US call or text the 988 Suicide & Crisis Lifeline right now. Dosing is reported strictly as seen in the literature, never as a recommendation.*

## How might peptides help with depression?

Neuroplasticity-centered models of depression hold that chronic stress and low **brain-derived neurotrophic factor (BDNF)** signaling drive synaptic loss in mood-regulating circuits, and that effective antidepressants — SSRIs, exercise, ketamine — ultimately work by restoring BDNF/TrkB signaling and synaptic plasticity.[20](https://peptidevox.com/#r20) The peptides here are attractive *in theory* because they converge on exactly these pathways, but "plausible mechanism" is a hypothesis, not a clinical result, and most of the mechanistic work below is rodent.

The headline mechanism is neurotrophin upregulation. Semax produces rapid, region-specific induction of BDNF protein and TrkB phosphorylation in rat hippocampus, and raises plasma BDNF in humans after stroke; Selank increases hippocampal BDNF in rats; and Cerebrolysin is marketed as a neurotrophic preparation claimed to mimic BDNF/NGF activity and raises BDNF in animal depression models.[17](https://peptidevox.com/#r17)[19](https://peptidevox.com/#r19)[4](https://peptidevox.com/#r4) The peptides also modulate monoamines: Semax amplifies dopaminergic signaling and raises serotonin-metabolite tone in rodent striatum, and Selank's neurochemical profile combines antidepressant- and psychostimulant-like actions via brain monoaminergic activation.[18](https://peptidevox.com/#r18)[13](https://peptidevox.com/#r13) Both Semax and Selank raise endogenous enkephalin tone, and Cerebrolysin reduces oxidative stress in rodent depression models.[5](https://peptidevox.com/#r5) The critical caveat is that every one of these mechanisms is necessary-but-not-sufficient logic: a compound can raise BDNF or 5-HIAA in a rat and still do nothing measurable for a depressed human. You can read the pivotal Cerebrolysin stroke trial, in which depression was a secondary endpoint, at [PubMed Central (PMC4689177)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4689177/).

## Which peptides have the best evidence, ranked?

The table below ranks each peptide by how close its *human* data comes to a depression endpoint. Only Cerebrolysin touches human mood at all — and only as a secondary outcome; the rest are ranked by proximity.

  Peptides for depression — evidence at a glance

    PeptideBest human evidence for depressionGrade

    CerebrolysinSecondary GDS benefit in stroke (CARS); null on TBI depression subscaleB
    SelankNone for depression; human data is in anxiety/neurastheniaC
    SemaxNone; a 2008 hypothesis paper plus animal stress modelsC-D

**Cerebrolysin** is the evidence leader, but the ceiling is low. It is the only peptide here with any *human* mood data — always as a secondary outcome in neurological-recovery populations, never in primary MDD. In the randomized, placebo-controlled CARS stroke trial (30 mL/day IV for ~21 days, n≈205), the Geriatric Depression Scale was among the secondary measures showing a "medium" benefit favoring Cerebrolysin at day 90, though no standalone GDS p-value was reported.[1](https://peptidevox.com/#r1) In moderate/severe TBI, a retrospective CAPTAIN-II analysis (n=125) found a large effect on anxiety but *no* statistically significant between-group difference on depression.[2](https://peptidevox.com/#r2) A 2025 scoping review concluded its psychiatric evidence base is limited.[3](https://peptidevox.com/#r3) Its animal antidepressant data — reserpine-model reversal, lithium potentiation, post-ischemic models — are more consistent than the human depression data.[4](https://peptidevox.com/#r4)[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) Grade B, with the caveat that "B" rests on secondary endpoints, not a dedicated depression trial.

**Selank** has genuine, dedicated *animal* antidepressant data — reduced forced-swim immobility and reversed anhedonia in genetically depression-prone WAG/Rij rats and stressed BALB/c mice — but for depression in humans, the cupboard is empty.[9](https://peptidevox.com/#r9) Its only human trial was in anxiety and neurasthenia, with an anti-fatigue component that overlaps depressive symptoms but is not a depression endpoint.[10](https://peptidevox.com/#r10) Grade C for depression. **Semax** is mechanistically the most "antidepressant-shaped" of the three, but its depression evidence is the weakest: no human depression trial exists, the much-cited "Semax for depression" reference is a 2008 hypothesis commentary presenting no original data, and its antidepressant-like effects appear only in stress-challenged rodents.[15](https://peptidevox.com/#r15)[16](https://peptidevox.com/#r16) Grade C-to-D.

Proven vs hyped
Proven in humans for depression: nothing. Hyped: a specific Cerebrolysin "18.4 vs 12.1 HDRS-point" MDD trial or 14-RCT review that circulates on vendor pages but corresponds to *no* study indexed in PubMed; "Selank/Semax are natural antidepressants" (animal-only); and "raising BDNF fixes depression" (a biomarker is not the illness). Anyone presenting any of these as a proven antidepressant is ahead of the evidence.[1](https://peptidevox.com/#r1)[15](https://peptidevox.com/#r15)

## What is the FDA and WADA status in 2026?

None of the three is FDA-approved as an antidepressant, or for any indication, in the US. Semax and Selank are sold only as research chemicals "not for human consumption," and **Semax is scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026** regarding §503A compounding — a review of compounding eligibility, not an efficacy or safety endorsement.[21](https://peptidevox.com/#r21) Selank's §503A compounding nomination was previously withdrawn and not added to the bulks list. Cerebrolysin is neither FDA-approved nor marketed in the US, though it is used in parts of Europe, Asia and Russia. Off any compounding list does not equal FDA-approved, and none of this speaks to depression efficacy.

For athletes the picture is unforgiving. None of the three is individually named on the WADA Prohibited List, but as non-approved substances all are captured by the S0 (non-approved substances) catch-all and should be treated by tested athletes as prohibited at all times.[22](https://peptidevox.com/#r22) "Research chemical" labeling confers no anti-doping protection.

## How safe are these peptides, and what does the evidence not support?

Long-term and psychiatric-population safety data are sparse to absent for all three. Cerebrolysin is parenteral only, with common injection-site reactions and labeled additive effects with antidepressants plus reported BP elevation when high doses are combined with high-dose MAOIs.[8](https://peptidevox.com/#r8) Selank and Semax are intranasal with reportedly mild effects (headache, nasal irritation, nausea); Selank potentiates benzodiazepines and Semax potentiates stimulant/dopaminergic effects in animals, so combining with CNS-active drugs warrants caution, and human interaction data are essentially absent.[12](https://peptidevox.com/#r12)[18](https://peptidevox.com/#r18) US-sourced research-chemical peptides also carry real purity, sterility and dosing-accuracy risks. Do not stop or replace a prescribed antidepressant to try a peptide, and do not combine without clinician oversight.

The evidence does **not** support several common claims. "A peptide is a proven treatment for major depressive disorder" is false: there is no adequately powered, dedicated, placebo-controlled human RCT with depression as the primary endpoint for any of them.[3](https://peptidevox.com/#r3) "A specific Cerebrolysin MDD trial showing large HDRS improvement exists" is unverified vendor lore that matches no PubMed-indexed study.[1](https://peptidevox.com/#r1) "A rat forced-swim or sucrose-preference result is a human antidepressant claim" confuses hypothesis-generating animal work for efficacy.[9](https://peptidevox.com/#r9)[16](https://peptidevox.com/#r16) And "raising BDNF fixes depression" reduces a complex disorder to a single biomarker.[20](https://peptidevox.com/#r20)

**Bottom line.** From a root-cause, evidence-first perspective, these peptides are best understood as experimental neurotrophic and monoaminergic modulators with biologically plausible but largely unproven mood effects in humans. Cerebrolysin is the only one with any human depression-relevant outcome, and even that is secondary, mixed, and never tested as a primary MDD treatment. None is a substitute for evidence-based depression care — therapy, lifestyle and root-cause work, and, where appropriate, established medication. Regulatory facts here are current as of June 2026; the July 24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date. If you are struggling, please talk to a professional — in crisis, call or text 988 in the US.

---
Source: https://peptidevox.com/energy-cognition-mood/peptides-for-depression
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt